Previous 10 | Next 10 |
home / stock / nlspw / nlspw news
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous ...
Oral presentation sharing significant phase 2 results of Mazindol ER in Adults with Narcolepsy Type 1 and Type 2 Five abstracts demonstrating NLS focus on and investment in hypersomnia disorders and rare and complex neurologic diseases ZURICH, SWITZERLAND / ACCESSWIRE / May 4, 2023 / N...
ZURICH, SWITZERLAND / ACCESSWIRE / May 2, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disor...
ZURICH, SWITZERLAND / ACCESSWIRE / April 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sy...
Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the open label extension (OLE) study Patients treated with placebo in the randomized Phase 2 trial and who subsequently received Mazindol ER in the OLE study achieved compar...
ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system dis...
Six-month Open Label Extension (OLE) study for patients that completed the POLARIS Phase 2 randomized, double-blind study has achieved its final patient visit 87% of patients who completed the POLARIS Phase 2 study requested to continue monotherapy treatment with Mazindol ER in the six-month...
ZURICH, SWITZERLAND / ACCESSWIRE / January 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous ...
The orexin deficit is believed to be the root cause of narcolepsy Mazindol ER is the most advanced Orexin-2 partial receptor agonist in development for the treatment of narcolepsy and other rare sleep disorders Mazindol ER is a first in class, unique dual mechanism of action as pan-mono...
Management to Discuss Pipeline Goals and Development Strategies across four Preclinical and 2 Clinical Programs across Multiple Central Nervous System (CNS) Disorders NLS to Webcast its R&D Day Event Tuesday, January 31 at 10:00am EST ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2...
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Warrant Company Name:
NLSPW Stock Symbol:
NASDAQ Market:
NLS Pharmaceutics Ltd. Warrant Website:
ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sys...
ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical re...
ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received noti...